IS4146A - Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara - Google Patents

Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara

Info

Publication number
IS4146A
IS4146A IS4146A IS4146A IS4146A IS 4146 A IS4146 A IS 4146A IS 4146 A IS4146 A IS 4146A IS 4146 A IS4146 A IS 4146A IS 4146 A IS4146 A IS 4146A
Authority
IS
Iceland
Prior art keywords
proton pump
oral administration
pharmaceutical preparation
pump blockers
blockers
Prior art date
Application number
IS4146A
Other languages
English (en)
Other versions
IS1694B (is
Inventor
Arthur Olovson Stig-Göran
Gunnar Pilbrant Åke
Original Assignee
Ab Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Astra filed Critical Ab Astra
Publication of IS4146A publication Critical patent/IS4146A/is
Publication of IS1694B publication Critical patent/IS1694B/is

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS4146A 1993-04-30 1994-04-06 Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara IS1694B (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939301489A SE9301489D0 (sv) 1993-04-30 1993-04-30 Veterinary composition

Publications (2)

Publication Number Publication Date
IS4146A true IS4146A (is) 1994-10-31
IS1694B IS1694B (is) 1998-04-20

Family

ID=20389791

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4146A IS1694B (is) 1993-04-30 1994-04-06 Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara

Country Status (33)

Country Link
US (1) US5731002A (is)
EP (1) EP0696921B1 (is)
JP (1) JP3872509B2 (is)
KR (1) KR100324451B1 (is)
CN (1) CN1100570C (is)
AT (1) ATE199060T1 (is)
AU (1) AU678830B2 (is)
BR (1) BR9406363A (is)
CZ (1) CZ285191B6 (is)
DE (1) DE69426669T2 (is)
DK (1) DK0696921T3 (is)
EE (1) EE03137B1 (is)
EG (1) EG20401A (is)
ES (1) ES2155473T3 (is)
FI (1) FI955124A (is)
GR (1) GR3035831T3 (is)
HR (1) HRP940267A2 (is)
HU (1) HUT74868A (is)
IL (1) IL109245A (is)
IS (1) IS1694B (is)
LT (1) LT3263B (is)
MA (1) MA23170A1 (is)
NO (1) NO312435B1 (is)
NZ (1) NZ265728A (is)
PL (1) PL176755B1 (is)
PT (1) PT696921E (is)
RU (1) RU2131267C1 (is)
SE (1) SE9301489D0 (is)
SG (1) SG52540A1 (is)
SK (1) SK280465B6 (is)
TN (1) TNSN94035A1 (is)
WO (1) WO1994025070A1 (is)
YU (1) YU22794A (is)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
AU773696B2 (en) * 1998-10-06 2004-06-03 Mars, Incorporated Animal stereotypy
EA004683B1 (ru) 1999-02-23 2004-06-24 Мерк Энд Ко., Инк. Фармацевтическая композиция, содержащая омепразол
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
AU2001296908A1 (en) * 2000-09-29 2002-04-08 Geneva Pharmaceuticals, Inc. Proton pump inhibitor formulation
EP1341523B1 (en) * 2000-12-07 2013-01-23 Nycomed GmbH Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
JP4241041B2 (ja) 2000-12-07 2009-03-18 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸分解性活性成分を含有するペースト形の医薬品製造物
DE10061135C1 (de) * 2000-12-07 2002-11-07 Byk Gulden Lomberg Chem Fab Pharmazeutische Zubereitung in Form einer Paste enthaltend einen säurelabilen Wirkstoff
US20020192299A1 (en) * 2000-12-28 2002-12-19 Rajneesh Taneja Pharmaceutical compositions of a non-enteric coated proton pump inhibitor with a carbonate salt and bicarbonate salt combination
JP2005521662A (ja) * 2002-01-25 2005-07-21 サンタラス インコーポレイティッド プロトンポンプ阻害剤の経粘膜送達
CO5400144A1 (es) * 2002-03-11 2004-05-31 Novartis Ag Compuestos organicos
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040006109A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
US20040081671A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of non-enterically coated acid-labile drugs
WO2004004690A1 (en) * 2002-07-03 2004-01-15 Abbott Laboratories Liquid dosage forms of proton pump inhibitors
US20040005362A1 (en) * 2002-07-03 2004-01-08 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20040082618A1 (en) * 2002-07-03 2004-04-29 Rajneesh Taneja Liquid dosage forms of acid labile drugs
US20070243251A1 (en) * 2002-12-20 2007-10-18 Rajneesh Taneja Dosage Forms Containing A PPI, NSAID, and Buffer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
JP2006518751A (ja) * 2003-02-20 2006-08-17 サンタラス インコーポレイティッド 胃酸の急速かつ持続的な抑制のための新規製剤、オメプラゾール制酸剤複合体−即時放出物
WO2005004921A1 (en) * 2003-07-11 2005-01-20 Astrazeneca Ab Solid composition comprising a proton pump inhibitor
US20050031700A1 (en) * 2003-07-18 2005-02-10 Sanatarus, Inc. Pharmaceutical formulation and method for treating acid-caused gastrointestinal disorders
CA2531564C (en) * 2003-07-18 2016-01-19 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
CA2554271A1 (en) * 2004-02-10 2005-08-25 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent
GB0403165D0 (en) * 2004-02-12 2004-03-17 Ct Novel uses for proton pump inhibitors
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20060134210A1 (en) * 2004-12-22 2006-06-22 Astrazeneca Ab Solid dosage form comprising proton pump inhibitor and suspension made thereof
JP2006176461A (ja) * 2004-12-24 2006-07-06 Dai Ichi Seiyaku Co Ltd 粒状物
EP1698233A1 (en) * 2005-03-01 2006-09-06 Bayer HealthCare AG Reduction of digestibility of phosphorus in animal nutrition
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
WO2007122478A2 (en) * 2006-04-20 2007-11-01 Themis Laboratories Private Limited Multiple unit compositions
CH698658B1 (de) * 2006-04-24 2009-09-30 Mepha Ag Orale pharmazeutische Formulierung mit schneller Freisetzung für Pyridylmethylsulfinyl-Benzimidazole.
WO2007138606A2 (en) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Multiple unit pharmaceutical formulation
PL2046334T3 (pl) 2006-07-25 2015-02-27 Vecta Ltd Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
CA2703008A1 (en) * 2007-11-15 2009-05-22 Novartis Ag Anthelmintic paste comprising praziquantel, a macrolide lactone, cyclodextrin and a thickener
US20090227633A1 (en) * 2008-03-04 2009-09-10 Bassam Damaj Methods to inhibit tumor cell growth by using proton pump inhibitors
WO2013058996A1 (en) * 2011-10-19 2013-04-25 R.P. Scherer Technologies, Llc Two phase pharmaceutical delivery system
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
AU2016404808A1 (en) * 2016-04-29 2018-12-13 Alan Thompson Veterinary composition
CN107468652A (zh) * 2016-06-07 2017-12-15 北京新领先医药科技发展有限公司 一种固体干混悬温敏凝胶剂及其制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
WO2018031935A1 (en) 2016-08-11 2018-02-15 Adamis Pharmaceuticals Corporation Drug compositions
EP3720844A4 (en) 2017-12-08 2021-08-11 Adamis Pharmaceuticals Corporation MEDICINAL COMPOSITIONS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL22368A (en) * 1963-11-19 1969-01-29 Merck & Co Inc 2,5(or 6)-bis-heteroaryl substituted benzazoles
BE792990A (fr) * 1971-12-23 1973-06-19 Shell Int Research Procede de lutte contre les endoparasites chez les chevaux
IL75400A (en) 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
AU4640985A (en) 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5215974A (en) * 1986-11-21 1993-06-01 Aktiebolaget Hassle Certain pyridyl[(methylthio- or methyl sulfinyl)-2 benzimidazol-2-yl]N-methyl phosphonates useful for treating gastric-acid secretion related diseases
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
DK130287D0 (da) * 1987-03-13 1987-03-13 Benzon As Alfred Oralt praeparat
YU48263B (sh) 1991-06-17 1997-09-30 Byk Gulden Lomberg Chemische Fabrik Gmbh. Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
WO2011034149A1 (ja) 2009-09-18 2011-03-24 旭硝子株式会社 二次電池用非水電解液

Also Published As

Publication number Publication date
RU2131267C1 (ru) 1999-06-10
DK0696921T3 (da) 2001-03-19
FI955124A0 (fi) 1995-10-27
US5731002A (en) 1998-03-24
DE69426669T2 (de) 2001-07-05
NO954240D0 (no) 1995-10-23
DE69426669D1 (de) 2001-03-15
YU22794A (sh) 1998-05-15
EP0696921A1 (en) 1996-02-21
BR9406363A (pt) 1996-02-27
ES2155473T3 (es) 2001-05-16
CN1100570C (zh) 2003-02-05
SK135495A3 (en) 1997-03-05
CZ285191B6 (cs) 1999-06-16
NO954240L (no) 1995-10-23
HU9503085D0 (en) 1995-12-28
TNSN94035A1 (fr) 1995-04-25
SG52540A1 (en) 1998-09-28
PL176755B1 (pl) 1999-07-30
EG20401A (en) 1999-02-28
HRP940267A2 (en) 1996-10-31
WO1994025070A1 (en) 1994-11-10
PL311276A1 (en) 1996-02-05
ATE199060T1 (de) 2001-02-15
PT696921E (pt) 2001-06-29
IL109245A0 (en) 1994-11-28
AU6693894A (en) 1994-11-21
LT3263B (en) 1995-05-25
GR3035831T3 (en) 2001-08-31
JP3872509B2 (ja) 2007-01-24
EE03137B1 (et) 1998-12-15
KR100324451B1 (ko) 2002-11-01
AU678830B2 (en) 1997-06-12
LTIP1920A (en) 1994-11-25
CZ282595A3 (en) 1996-04-17
IL109245A (en) 2000-07-16
EP0696921B1 (en) 2001-02-07
SE9301489D0 (sv) 1993-04-30
JPH08509493A (ja) 1996-10-08
NO312435B1 (no) 2002-05-13
IS1694B (is) 1998-04-20
FI955124A (fi) 1995-10-27
HUT74868A (en) 1997-02-28
SK280465B6 (sk) 2000-02-14
CN1122109A (zh) 1996-05-08
NZ265728A (en) 1996-12-20
MA23170A1 (fr) 1994-12-31

Similar Documents

Publication Publication Date Title
IS4146A (is) Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
IS2706B (is) Lyfjasamsetning sem inniheldur róteindadæluhindra
ATE211907T1 (de) Osmotisches arzneimittelfreisetzungssystem
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
MX9604354A (es) Nueva forma de dosis farmaceutica oral.
ATE391495T1 (de) Matrixsystem mit verzögerter freisetzung für hochlösliche wirkstoffe
HUP0002490A2 (hu) Csersav-polimer kompozíciók gyógyászati anyagok szabályozott leadására, különösen a szájüregben
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration
MX9710093A (es) Uso de aminas alilicas.
CA2161683A1 (en) Veterinary composition containing a proton pump inhibitor
WO2001041771A3 (de) Acetylsalicylsäure enthaltendes transdermales system zur behandlung von migräne
AU1305999A (en) (+)-ephedrine as a sympathomimetic drug
UA35918A (uk) Спосіб лікування червоного плескатого лишаю слизової оболонки порожнини рота